Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Next Previous
Trial Profile

A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Neoantigen DNA vaccine MedImmune/Washington University School of Medicine (Primary) ; Nivolumab (Primary) ; Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 18 Sep 2018 Planned End Date changed from 5 Sep 2023 to 14 Sep 2023.
    • 18 Sep 2018 Planned primary completion date changed from 5 Oct 2021 to 14 Oct 2021.
    • 05 Sep 2018 Planned End Date changed from 31 Aug 2023 to 5 Sep 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top